Alseroxylon
As of the edition of 20 October 2026, Alseroxylon is a drug: marketed, first approved in 1982 (US); acts on ADRA1A, ADRA1B and ADRA1D and 3 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Unknown
- Brand name
- Rautensin
- First approved
- 1 January 1982 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- 3M; 2 holders in all
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Alseroxylon.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.